Displaying drugs 2326 - 2350 of 2957 in total
PTC299
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF...
Investigational
Matched Description: … orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor …
CAM-2029
CAM2029 is a new ready-to-use, long-acting octreotide formulation being developed for the long-term treatment of acromegaly, carcinoid syndrome and vasoactive intestinal peptide (VIP)-producing tumours. CAM2029 was found to provide long-acting release of octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor 1 (IGF-1) over the...
Investigational
Matched Description: … octreotide resulting in a statistically significant suppression of a clinical biomarker insulin-like growth factor …
Rocaglamide
Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides. Rocaglamides are secondary metabolites of the plant genus Aglaia, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties. Reports...
Experimental
Dirucotide
Dirucotide is a synthetically prepared peptide. In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta,...
Investigational
SB-559448
SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor that promotes growth and production of blood platelets. This drug is developed by GlaxoSmithKline and used to treat Thrombocytopenia.Thrombocytopenia (decreased platelet count) is a common side effect of many chemotherapies and can lead to uncontrolled...
Investigational
Matched Description: … SB-559448 is a small-molecule drug that mimics the activity of thrombopoietin (TPO), a protein factor …
Bardoxolone methyl
Investigational
Tifuvirtide
Tifuvirtide is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast-track designation from the FDA and is in Phase I/II clinical testing.
Investigational
Matched Categories: … Human Immunodeficiency Virus Proteins ... env Gene Products, Human Immunodeficiency Virus …
Pegpleranib
Investigational
UB-612
The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components . The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell...
Investigational
Matched Description: … vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human …
Matched Categories: … Complex Mixtures …
Matched Categories: … Complex Mixtures …
Elsiglutide
Investigational
VA-MENGOC-BC®
VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. The OMVs contain over 100 proteins, and are derived from meningococcal group B and capsular polysaccharide of meningococcal group C. As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and...
Investigational
Matched Description: … Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein ... As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
Inosine
A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose. It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules. (Dorland,...
Experimental
Investigational
TG4010
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory...
Investigational
Matched Description: … A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin …
Matched Categories: … Complex Mixtures …
Matched Categories: … Complex Mixtures …
MK-4721
MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell Antigen (PSCA), an antigen expressed at significant levels on tumor cells from the majority of patients with all stages of prostate, pancreatic and bladder cancers.
Investigational
Matched Description: … MK-4721 is a fully human monoclonal antibody directed to Agensys’ proprietary target Prostate Stem Cell …
Tetrathiomolybdate
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is...
Investigational
ATP
An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter.
Investigational
Nutraceutical
Grn163l
GRN163L is a novel anti-cancer drug. It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both cell culture systems and animal models. Study of this drug shows the...
Investigational
Matched Description: … It has been characterized preclinically and shown to inhibit telomerase in human tumor cells of many ... cancer types (including lung, breast, prostate, liver, and early stage of human breast cancer), in both …
BAX 335
BAX 335 is an adeno-associated virus vector 8 (AAV8)–based FIX gene therapy being investigated for the treatment of hemophilia B.
Investigational
Matched Categories: … Blood Coagulation Factors …
Albinterferon Alfa-2B
Albumin-interferon alpha (Albuferon) is a novel, long-acting form of interferon alpha. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the company's proprietary albumin fusion technology. Human...
Investigational
Matched Description: … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C. ... Human Genome Sciences modified interferon alpha to improve its pharmacological properties by using the ... In response to an FDA ruling, Novartis and Human Genome Sciences announced on October 5, 2010 that they …
Apatorsen
Apatorsen is a second generation antisense drug which in preclinical experiments, inhibits production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human cancers including prostate, lung, breast, ovarian, bladder, renal, pancreatic, multiple myeloma and liver cancer.
Investigational
Matched Description: … production of Heat Shock Protein 27 (Hsp27) a cell survival protein found at elevated levels in many human …
Tideglusib
Tideglusib is under the investigation for the development of treatments for Alzheimer's disease and for progressive supranuclear palsy. It is reported to be a potent anti-inflammatory and neuroprotective that is a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3). Tideglusib is being developed by the Spanish pharmaceutic company Zeltia...
Investigational
Withdrawn
VPM1002
The bacille Calmette-Guérin (BCG) vaccine protects against severe extrapulmonary forms of tuberculosis (TB) but does not adequately protect against pulmonary TB -- the most prevalent form of TB. This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials …
Matched Categories: … Complex Mixtures …
Matched Categories: … Complex Mixtures …
Displaying drugs 2326 - 2350 of 2957 in total